EXECUTIVE LEADERSHIP
Meet Elektrofi’s executive leaders and biotech pioneers. This team is responsible for the company’s strategic direction, its operational oversight, and for enabling the company’s vision to reimagine the delivery of life saving and life changing medicines.
-
Chief Executive Officer
Chase Coffman is the Chief Executive Officer and co-founder of Elektrofi. Since the company’s inception in 2015, Chase has combined his deep expertise in technology and roots in science with his passion for solving challenges to change people’s lives.
His extensive background in fluid mechanics and microsystems helped form the foundation for Elektrofi’s ultra-high concentration microparticle platform technology. As an academic, Chase focused on paradigm-shifting space propulsion technologies for nanosatellites, related laser micromachining techniques, and electrohydrodynamic theories that have applications in a wide range of fields. This proven track record, coupled with his collaborative approach to co-creation, enables trusted relationships with Elektrofi’s partners and colleagues alike.
Prior to founding Elektrofi, he served as a Space Technology Research Fellow with National Aeronautics and Space Administration (NASA).
Chase holds a Ph.D. in Philosophy and a Master of Science in Aeronautics and Astronautics from the Massachusetts Institute of Technology. He earned his Bachelor of Science in Aerospace Engineering from the University of Florida.
-
Greg-DeFilippis
Chief Business OfficerGreg DeFilippis is the Chief Business Officer, responsible for Elektrofi’s go-to-market strategy, including revenue optimization, partnerships, and corporate development.
Greg is an experienced clinical and commercial leader with more than 20 years’ experience of pharmaceutical, biotech, and medical device industry experience. Having held C-suite and senior leadership positions he has a proven track record of successfully forming strategic partnerships, developing, launching and growing products with a focus on driving profitable revenue growth, building, and leading high-performing organizations.
Greg served as Chief Business Officer of Halozyme, leading the company’s licensing strategy for its technology and autoinjector device platforms as well as its strategic partnering strategy. Prior to Halozyme he served as Senior Vice President, Device Business and Alliances for Antares Pharma. Over the course of his career, Greg has helped partner, develop, and launch 17+ therapies including Xyosted®, Otrexup®, and the first generic AB rated EpiPen. He has held increasing roles of responsibilities for companies including Teva Pharmaceuticals, Barr Laboratories, Pliva, Actavis, and Alpharma.
Greg holds a Master of Business Administration in Finance from Fairleigh Dickinson University and a Bachelor of Science in Industrial and Systems Engineering from Virginia Tech. Greg is a certified Lean Six Sigma Master Black Belt.
-
Vikki-Sluzky
Chief Technology OfficerVictoria Sluzky is the Chief Technology Officer (CTO) responsible for Elektrofi’s pharmaceutical development process including process development, formulation, analytics, and innovation. She will also oversee the company’s Chemical, Manufacturing, and Controls (CMC) groups, Regulatory, and related processes in support of advancing the Company’s clinical programs. As an executive leader, Victoria has guided analytical, formulation, and process development teams to transform the vision of research scientists into manufacturing processes and quality control systems that withstood rigorous regulatory and compliance requirements, enabling the availability of new therapies.
Specializing in quality, manufacturing, and pharmaceutical development of gene therapy and biologic therapeutics, Victoria brings more than 30 years of healthcare and biotechnology experience to Elektrofi, including 19 years of significant contributions to BioMarin Pharmaceutical, where she most recently served as Senior Vice President of Technical Development. Victoria earlier roles in biotechnology focused on leading analytical and formulation development groups at Onyx Pharmaceutical, COR Therapeutics, and Scios. Her strategic vision and contributions led to the approval of nine commercial products including Aldurazyme®, Brineura®, Integrilin®, Kuvan®, Naglazyme®, Palynziq®, Roctavian™, Vimizim®, and Voxzogo®.
Victoria holds a Ph.D. in Chemical Engineering from Massachusetts Institute of Technology and a Bachelor of Science in Chemical Engineering from Stanford University. She serves as a Fellow of American Institute of Medical and Biological Engineers, a non-profit organization headquartered in Washington, D.C., representing the most accomplished individuals in the fields of medical and biological engineering.
-
Paulette-Gangemi
Chief Human Resource OfficerPaulette Gangemi is the Chief Human Resource Officer, responsible for developing and executing Elektrofi’s human resource strategy in support of business growth, the employee experience, and company culture. She has a 20 year-proven track record of creating cross-collaborative, agile teams that accelerate product development success by enabling core business partners.
An accomplished human resource leader with deep business acumen, particularly in high growth markets, Paulette specializes in building and executing strategic plans, systems, and processes for dynamic and high performing pharmaceutical and biotech companies in technical and highly regulated environments.Prior to joining Elektrofi, Paulette served in roles such as Chief Human Resources Officer for Princeton Plasma Physics Lab, Head of Employee Relations and Business Practices for Daiichi Sankyo, and Head of Human Resources, Pharma Services Division of ThemoFisher Scientific. She’s supported Biologics License Applications (BLA) and enabled corporate, clinical, and commercial leadership teams successfully launch and support more than 10+ therapeutics including Enhertu®, Erbitux®, Savaysa®, Turaliov®, Benicar®, and Evozak®.
Earlier in her career, she built and managed the HR function for Daiichi Sankyo’s only US pharmaceutical plant and was an integral in Eli Lilly’s successful acquisition of ImClone leading HR-specific due diligence, pre-close planning, post-close integration activities.
Paulette holds a Master in Labor and Management Relations from Rutgers University and a Bachelor of Arts from Green Mountain College. She holds a Wharton Executive Education Chief Human Resources Officer certificate from The Wharton School. Paulette is a certified New Jersey Emergency Medical Technicians (EMT) and is a trained first responder for the Blue Mountain Resort Ski Patrol. Paulette is a member of Chief, an organization committed to developing and supporting women in leadership.
-
Daniel-Dadon
Vice President and Head of ScienceDaniel B. Dadon is a Vice President and Head of Science responsible multiple technical, corporate, and business functions, including governing the company’s translational, formulation, and analytical R&D priorities. He is a biologist and one of the scientific co-founders of Elektrofi.
Prior to joining Elektrofi, Daniel served as the Scientific Strategy and Corporate Development Fellow at Evelo Biosciences, a Flagship Pioneering company, working on microbiome therapeutics. As a National Science Foundation (NSF) Fellow at the Whitehead Institute of Massachusetts Institute of Technology (MIT), Daniel studied the underlying principles of the transcriptional control of cell identity. While at MIT he contributed to science through seminal publications and licensed patents in the spaces of 3D genomics/epigenomics, genome engineering (CRISPR, TALEN), artificial transcription factor technology, and chromatin proteomic mass spectrometry. Prior, Daniel was in the HHMI McCammon Laboratory at UC San Diego performing computational biophysics to conduct molecular dynamic and docking simulations to identify small molecule inhibitors of swine (H1N1) flu. He also worked at Biogen Idec in the Process Development group optimizing the chromatographic purification of Tysabri®. Before Biogen Idec, he started his scientific career investigating various gene therapy approaches at the Center for Neural Repair lab at the UC San Diego Medical School.
Daniel holds a Ph.D. in Biology from MIT and a Bachelor of Science in Molecular Biology from UC San Diego. He’s completed coursework at the Massachusetts Institute of Technology Sloan School of Management and has made scientific contributions through groundbreaking publications and licensed patents.
-
Lyndon-Charles
Vice President and Head of Program Management and StrategyLyndon Charles is Vice President and Head of Program Management and Strategy, responsible for driving Elektrofi’s partnership programs and pipeline, and ensuring program goals are being met collaboratively, with efficiency, quality, and speed. He leverages his broad range of experience to enable a holistic view of our programs to prioritize activities, proactively manage challenges and find synergies, and actively pursue shared goals for developing and commercializing assets.
Lyndon is a biomedical engineer and scientist who is passionate about leading diverse teams to develop new technologies in the pursuit of solving complex biomedical problems.
Prior to joining Elektrofi, he served as a postdoctoral Research Scientist at the Massachusetts Institute of Technology, a Research Assistant at the University of Connecticut, and a National Science Foundation Research Scholar awardee at École Polytechnique Fédérale de Lausanne (EPFL). Across these roles, Lyndon managed cross functional teams and worked on highly collaborative academia-industry partnerships with companies such as Sanofi, BioTime, and Aruna BIO. Lyndon has authored 11 peer reviewed papers in the fields of drug delivery, regenerative engineering, and aging. His proven expertise in the development of novel drug delivery technologies and their applications across regenerative medicine has led to intellectual property supporting the commercialization of products and launching of biotech startups.
Lyndon holds Ph.D. in Biomedical Science, and a Bachelor of Science in Biomedical Engineering from the University of Connecticut.
FUNCTIONAL LEADERSHIP
Meet the people behind Elektrofi. These leaders and teams power our innovative technology, science, and processes.
-
Drug Product Innovation
Paul Brown, Ph.D. leads the company’s Innovation team. In this role, he’s accountable for evolving and optimizing the company’s current technology platform and potential uses, while also exploring new methodologies and opportunities of impact. He is a physical chemist and one of the scientific co-founders of Elektrofi’s proprietary formulation technology platform. Paul plays a vital role in the company’s growth across drug product development, process scale-up, translation, and device selection.
Prior to joining Elektrofi, Paul worked at several research institutions, including the Massachusetts Institute of Technology, Oakridge National Laboratory, and the Rutherford Appleton Laboratory, where he authored 45 peer-reviewed papers in the fields of biology, materials science, chemical engineering, and physics. His proven expertise in interface and colloid science and its applications across pharmaceuticals, biotechnology, nanotechnology, and materials led to his developing 18 registered patents.
Paul holds a Ph.D. in Physical Chemistry and a Master in Chemistry from the University of Bristol.
-
Analytical Development
Tyler Carter leads the company’s Analytical Development team and is responsible for the development and implementation of methods associated with Elektrofi’s ultra-high concentration microparticle suspensions protein platform technology.
Tyler has more than 20 years of experience in academic and biotechnology sectors, including preclinical and clinical research across a wide range of protein-based pharmaceuticals, including monoclonal antibodies, antibody fragments, antibody-drug conjugates (ADCs), Fc-fusion proteins, hormones, enzymes, and peptides derived from multiple expression systems.
Prior to joining Elektrofi, Tyler served as a Senior Scientist with both Mersana Therapeutics and Momenta Pharmaceuticals. While at Mersana, Tyler developed methods for conjugate isoform identification and drug antibody ratio determination for multiple dolasynthen and immunosynthen programs. His contributions at Momenta (since acquired by Johnson & Johnson), contributed to the pre-clinical and clinical development for all biosimilar programs as well as M281 (novel anti-FcRn antagonist nipocalimab).
Tyler holds a Ph.D in Biochemistry and a Master of Science in Biotechnology from the University of Massachusetts Lowell. He earned his Bachelor of Science in Molecular, Cellular, and Developmental Biology from the University of New Hampshire.
-
Lab Operations and Facilities
Angela Hui leads the company’s lab operations and facilities teams, responsible for laboratory operations and facilities management to ensure the efficient and effective functioning of our scientific research and development efforts. She also oversees the company’s information technology systems.
She is an accomplished operations leader with proven experience designing lab spaces and management. Angela has significant expertise within the areas of lab operations oversight, facility design, and sample management. Prior to joining Elektrofi, Angela led a site team for SmartLabs and held roles of increasing responsibilities for 15 years at Amgen in R&D Lab operations. During this time, she supported its Discovery Research business focused on process optimization, cross-site alignment, and operational excellence.
Angela has a Bachelor of Science from Northeastern University. She is a board member of LabOps Unite Community, a global community of operations professionals, where she serves as vice chair and leads its mentorship program across the United States, Europe, and Canada.
-
Process Development
James Ivey leads the company’s Process Development team where he contributes expertise in particle engineering, particle physicochemical analytics, and particle-based drug delivery systems to advance Elektrofi’s ultra-high concentration protein formulation platform.
Prior to joining Elektrofi, James held roles at Pearl Therapeutics, MedImmune, and Aradigm. Most notably, as an early contributor at Pearl Therapeutics, he supported the development of its engineered particle formulation platform Aerosphere® which led to approval and commercialization of Airsupra™, Bevespi Aerosphere®, and Breztri Aerosphere®.
As particle engineer and scientist with more than a decade of industrial and academic experience in spray drying (atomization, particle formation, and particle separation/sampling), analysis of particle physicochemical properties, and particle-based drug delivery technologies, James has a proven ability in applying models and engineering principles to expedite formulation development, process development, and manufacturing scale-up of solid dosage forms.
James holds a Ph.D. in Mechanical Engineering from the University of Alberta and a Bachelor of Science in Mechanical Engineering from the University of California at Santa Barbara (UCSB). While at UCSB he was awarded the UCSB Regent’s Scholar.
-
Formulation Development
Chaitanya Sudrik leads the company’s Formulation Development team and is responsible the ongoing development of the company’s protein formulation technology platform.
Chaitanya is a respected thought leader, having authored and spoken on conferences on topics including protein stability, pre-formulation, and thermodynamics of protein-excipient interactions. He has authored several peer-reviewed articles on the topics of excipient-mediated protein stabilization, riboswitches, and optogenetics.
Prior to joining Elektrofi, Chaitanya conducted his post-doctoral training at the Molecular Engineering Laboratory at Massachusetts Institute of Technology where he conducted research on the development of high concentration protein formulations.
Chaitanya holds a Ph.D. in Chemical and Biological Engineering from Rensselaer Polytechnic Institute and a Bachelor of Science in Chemical Engineering from the Institute of Chemical Technology, Mumbai.
BOARD OF DIRECTORS
This team champions our purpose, our curiosity, and our ability to transform the future in biologics delivery by discovering better ways of doing things.
-
Constantine currently serves as a strategic advisor to a number of leading biotech and pharma companies, leveraging his broad experience in Corporate and Business Development.
His most recent full time role was Chief Business Officer at Albireo Pharmaceuticals, where he helped to execute the sale of the company to Ipsen Pharmaceuticals in March 2023. Prior to that, he served as Chief Business Officer of Boston Pharmaceuticals, where he executed over 20 licensing transactions in order to build the portfolio. Before joining Boston Pharmaceuticals, Constantine was Vice President and Chief Licensing Officer at Sanofi, where he was responsible for the global business development function.
He joined Sanofi following its acquisition of Genzyme in 2011 and initially assumed the role of regional head of Business Development for Sanofi's North American Pharmaceutical division. Prior to this position, he was a Vice President in Genzyme's Corporate Development group, which he joined in 2001 after 12 years at Eli Lilly in various roles.
-
Chase has extensive expertise in fluid mechanics and microsystems, propulsion technologies for nanosatellites, related laser micromachining techniques, and electrohydrodynamic theories. Prior to founding Elektrofi, he served as a Space Technology Research Fellow with National Aeronautics and Space Administration (NASA). Chase holds a Ph.D. in Philosophy and a Master of Science in Aeronautics and Astronautics from the Massachusetts Institute of Technology. He earned his Bachelor of Science in Aerospace Engineering from the University of Florida.
-
Charles L. Cooney is the Robert T. Haslam (1911) Professor of Chemical and Biochemical Engineering, Emeritus in the Department of Chemical Engineering at MIT and founding Faculty Director, Emeritus of the Deshpande Center for Technological Innovation at MIT. He has been involved as founder, advisor or board member of over 40 companies and currently sits on the Boards of Directors of Elektrofi, Hovione AG, Innovent Biologics (1801.HK), Iterative Health, Levitronix Technologies, LayerBio, and Boyd Biomedical. In addition, he is Trustee Emeritus of Boston Ballet, Advisor Emeritus of the Boston Symphony Orchestra and Chairman & Trustee of the Leventhal Map and Education Center.
-
Andrew is a Managing Director at Marshall Wace and helps lead the XO Healthcare Innovation fund, which focuses on late-stage private investments. Before this he was a Partner on the private innovation team at Palo Alto-based Vivo Capital, where he focused on private pharmaceutical and medical device companies. Prior to Vivo, he worked at McKinsey & Company in the Silicon Valley office in their pharmaceutical and medical products practice.
Dr. Goldberg is a US board-certified physician in both Critical Care Medicine and Emergency Medicine. He received his MD from The George Washington University School of Medicine in Washington, DC, and has held academic and clinical appointments at the Mayo Clinic, Stanford VA Palo Alto Medical Center, Oregon Health & Science University, the University of Arizona, and the Washington Township Medical Foundation.
-
Arman joined BVF Partners L.P. in 2015. Before BVF, he was an investment banking analyst in the global healthcare group at Barclays, where he focused on M&A, capital raises and client advisory in the biotechnology and pharmaceutical sectors. He holds a B.A. with honors in Economics from the University of Pennsylvania.
-
Jason Norris
Jason Norris is a co-founder of Elektrofi and is focused on building transformative companies that enable people to live fuller lives. In addition to his role with Elektrofi, he also serves on the Board of Directors of Mytide Therapeutics and Lapix Therapeutics. He began his career at Wachovia Bank and also served as a Managing Director for The Bernstein Companies. Jason earned a Master of Business Administration from Massachusetts Institute of Technology Sloan School of Management and a Bachelor of Arts from University of North Carolina Chapel Hill.
